174 related articles for article (PubMed ID: 20164660)
1. Anagrelide for the treatment of thrombocythaemia in daily clinical practice: a post-marketing observational survey on efficacy and safety performed in Germany.
Schmitz S; Stauch M; Schlag R
Onkologie; 2010; 33(1-2):39-44. PubMed ID: 20164660
[TBL] [Abstract][Full Text] [Related]
2. [Anagrelide in the treatment of thrombocythemia essential (ET)].
Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
Kornblihtt LI; Vassallu PS; Heller P; Molinas FC
Medicina (B Aires); 2002; 62(3):231-6. PubMed ID: 12150005
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.
Petrides PE; Gisslinger H; Steurer M; Linkesch W; Krumpl G; Schüller A; Widmann R
Clin Ther; 2009 Feb; 31(2):386-98. PubMed ID: 19302911
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia.
Mills AK; Taylor KM; Wright SJ; Bunce I; Eliadis P; Brigden MC; Seeley G; Bashford J; Olsen T; Rentoul A; Kelly C
Aust N Z J Med; 1999 Feb; 29(1):29-35. PubMed ID: 10200810
[TBL] [Abstract][Full Text] [Related]
6. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
[TBL] [Abstract][Full Text] [Related]
7. Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with Anagrelide.
Bellucci S; Legrand C; Boval B; Drouet L; Caen J
Br J Haematol; 1999 Mar; 104(4):886-92. PubMed ID: 10192455
[TBL] [Abstract][Full Text] [Related]
8. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
9. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
Burkhard R; Adam H; Widmer L; Honegger HP
Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
[TBL] [Abstract][Full Text] [Related]
10. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
[TBL] [Abstract][Full Text] [Related]
11. Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.
Griesshammer M
Expert Rev Hematol; 2009 Jun; 2(3):227-36. PubMed ID: 21082965
[TBL] [Abstract][Full Text] [Related]
12. [Anagrelide in primary thrombocythemia].
Knutsen H; Hysing J
Tidsskr Nor Laegeforen; 2001 May; 121(12):1478-82. PubMed ID: 11449771
[TBL] [Abstract][Full Text] [Related]
13. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany.
Petrides PE; Beykirch MK; Trapp OM
Eur J Haematol; 1998 Aug; 61(2):71-6. PubMed ID: 9714517
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.
Ito T; Hashimoto Y; Tanaka Y; Nakaya A; Fujita S; Satake A; Nakanishi T; Konishi A; Hotta M; Yoshimura H; Ishii K; Hashimoto A; Kondo T; Omura H; Shinzato I; Tanaka T; Nomura S
Eur J Haematol; 2019 Aug; 103(2):116-123. PubMed ID: 31107982
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].
Ge X; Yang L; Jin J; Qian W; Li J; Yang R; Cao X; Jiang B; Wang Z; Hou M; Zhang W; Xiao Z; Zhao Y; Gao D; Zhang X; Wang S; Sun A; Fu J; Su L; Li K
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):547-52. PubMed ID: 26304075
[TBL] [Abstract][Full Text] [Related]
16. Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide.
Cacciola RR; Cipolla A; Di Francesco E; Giustolisi R; Cacciola E
Am J Hematol; 2005 Sep; 80(1):81-3. PubMed ID: 16138352
[TBL] [Abstract][Full Text] [Related]
17. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
[TBL] [Abstract][Full Text] [Related]
18. Anagrelide: a review of its use in the management of essential thrombocythaemia.
Wagstaff AJ; Keating GM
Drugs; 2006; 66(1):111-31. PubMed ID: 16398570
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
Gotic M; Egyed M; Gercheva L; Warzocha K; Kvasnicka HM; Achenbach H; Wu J
Cardiovasc Toxicol; 2021 Mar; 21(3):236-247. PubMed ID: 33123978
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
